Baxter Swings to Q3 Loss Amid Kidney Care Divestiture Adjustments

TL;DR

**Baxter's Q3 loss is a messy but necessary step in its strategic pivot, but the post-divestiture adjustments are hitting harder than expected.**

AI Summary

Baxter International Inc. reported a net loss attributable to stockholders of $46 million for the three months ended September 30, 2025, a significant decline from a net income of $140 million in the prior-year quarter. This resulted in a basic loss per common share of $0.09, compared to basic earnings per share of $0.27 in Q3 2024. Net sales increased to $2.835 billion in Q3 2025 from $2.699 billion in Q3 2024, representing a 5% increase. However, gross margin decreased to $950 million from $1.033 billion, and cost of sales rose to $1.885 billion from $1.666 billion. The company completed the sale of its Kidney Care business to Carlyle for $3.80 billion in cash on January 31, 2025, recognizing a pre-tax gain of $115 million for the nine months ended September 30, 2025, though this was reduced by $55 million in Q3 2025 due to working capital adjustments. The North Cove facility, damaged by Hurricane Helene in September 2024, became fully operational by the end of Q1 2025, incurring $8 million in pre-tax net charges in Q3 2025 and $123 million for the nine months ended September 30, 2025, related to remediation and air freight costs. Total assets decreased to $21.067 billion as of September 30, 2025, from $25.782 billion at December 31, 2024, largely due to the divestiture of discontinued operations.

Why It Matters

Baxter's Q3 net loss and reduced gain from the Kidney Care divestiture signal a challenging transition period for investors, impacting short-term profitability and potentially future dividend stability. The successful divestiture, while causing initial accounting adjustments, aims to streamline Baxter's portfolio and focus on higher-growth areas, which could benefit long-term shareholders. For employees, the completion of the Kidney Care sale to Carlyle (now Vantive Health LLC) means a clear separation, potentially affecting roles and strategic priorities. Customers of the divested Kidney Care business are now served by Vantive, while Baxter's remaining customers will see a more focused product offering. The broader market will watch how Baxter leverages the $3.71 billion pre-tax cash proceeds to reduce debt and invest in innovation, especially in a competitive medical technology landscape.

Risk Assessment

Risk Level: medium — The company reported a net loss of $46 million for Q3 2025, a significant drop from a $140 million net income in Q3 2024. This is compounded by a $55 million reduction in the gain on sale of the Kidney Care business due to post-closing adjustments, indicating ongoing financial volatility during this strategic transition. Additionally, the $123 million in pre-tax charges for Hurricane Helene remediation for the nine months ended September 30, 2025, highlights operational risks.

Analyst Insight

Investors should closely monitor Baxter's capital allocation strategy following the Kidney Care divestiture, particularly how the $3.71 billion cash proceeds are used for debt reduction and reinvestment. Evaluate future earnings reports for signs of stabilization and growth in continuing operations, as the Q3 loss reflects significant one-time adjustments. Consider the long-term strategic benefits of a more focused portfolio against the short-term financial headwinds.

Financial Highlights

debt To Equity

1.91

revenue

$2.835B

operating Margin

6.1%

total Assets

$21.067B

total Debt

$9.500B

net Income

$(46)M

eps

$(0.09)

gross Margin

33.5%

cash Position

$1.726B

revenue Growth

+5%

Key Numbers

• $2.835B — Net Sales (Increased from $2.699B in Q3 2024, a 5% increase.)
• $(46)M — Net Income (Loss) Attributable to Baxter Stockholders (Swung from a $140M income in Q3 2024 to a loss in Q3 2025.)
• $(0.09) — Basic Income (Loss) Per Common Share (Decreased from $0.27 in Q3 2024.)
• $3.80B — Kidney Care Business Sale Price (Aggregate cash purchase price received from Carlyle.)
• $115M — Pre-tax Gain on Sale of Kidney Care Business (Recognized for the nine months ended September 30, 2025, before Q3 adjustments.)
• $55M — Reduction in Gain on Sale (Pre-tax reduction in Q3 2025 due to final working capital adjustments.)
• $123M — Hurricane Helene Related Charges (Pre-tax net charges for the nine months ended September 30, 2025.)
• $1.726B — Cash and Cash Equivalents (As of September 30, 2025, down from $1.764B at December 31, 2024.)
• $8.747B — Long-term Debt (As of September 30, 2025, reduced from $10.374B at December 31, 2024.)
• 514,055,805 — Common Stock Shares Outstanding (As of October 31, 2025.)

Key Players & Entities

• BAXTER INTERNATIONAL INC. (company) — registrant
• Carlyle Group Inc. (company) — acquirer of Kidney Care business
• Vantive Health LLC (company) — new name of divested Kidney Care business
• SEC (regulator) — Securities and Exchange Commission
• NYSE (regulator) — New York Stock Exchange
• Hurricane Helene (event) — natural disaster impacting North Cove facility
• $3.80 billion (dollar_amount) — aggregate purchase price for Kidney Care business
• $46 million (dollar_amount) — net loss attributable to Baxter stockholders for Q3 2025
• $140 million (dollar_amount) — net income attributable to Baxter stockholders for Q3 2024
• $55 million (dollar_amount) — pre-tax reduction of gain on sale of Kidney Care business in Q3 2025

FAQ

Risk Factors

• Supply Chain Disruptions and Facility Damage [medium — operational]: The North Cove facility experienced damage from Hurricane Helene in September 2024, incurring $8 million in pre-tax net charges in Q3 2025 and $123 million for the nine months ended September 30, 2025, related to remediation and air freight costs. While the facility became fully operational by the end of Q1 2025, such events highlight ongoing operational vulnerabilities and associated costs.
• Impact of Divestitures on Financials [medium — financial]: The sale of the Kidney Care business for $3.80 billion in cash on January 31, 2025, resulted in a pre-tax gain of $115 million for the nine months ended September 30, 2025, but was reduced by $55 million in Q3 2025 due to working capital adjustments. This divestiture significantly reduced total assets from $25.782 billion at December 31, 2024, to $21.067 billion at September 30, 2025.
• Declining Gross Margins [medium — market]: Gross margin decreased to $950 million in Q3 2025 from $1,033 million in Q3 2024, a decline of approximately 8%. This was accompanied by a rise in the cost of sales to $1.885 billion from $1.666 billion, indicating potential pricing pressures or increased input costs impacting profitability.

Industry Context

Baxter International operates in the highly competitive medical products and healthcare industry, facing global players in areas like renal care, medical devices, and pharmaceuticals. Key trends include increasing demand for innovative medical technologies, a focus on cost containment by healthcare systems, and evolving regulatory landscapes worldwide. The company's strategic divestitures, such as the Kidney Care business, indicate a focus on optimizing its portfolio for future growth areas.

Regulatory Implications

The medical device industry is subject to stringent regulations from bodies like the FDA and EMA, requiring significant compliance efforts and investment in quality control. Changes in healthcare policies and reimbursement rates can also impact revenue and profitability. The company's operational disruptions, like the hurricane damage, underscore the importance of robust business continuity and disaster recovery plans to ensure regulatory compliance and product availability.

What Investors Should Do

1. Monitor margin trends closely.
2. Analyze the impact of divestitures on future growth.
3. Evaluate the effectiveness of operational recovery and cost management.

Key Dates

• 2025-01-31: Completion of Kidney Care Business Sale — The sale for $3.80 billion in cash impacts the company's asset base and future revenue streams, while generating a significant gain, albeit with adjustments.
• 2024-09-30: Hurricane Helene Damage to North Cove Facility — This event led to substantial remediation and air freight costs, impacting operating results in subsequent periods and highlighting supply chain and operational risks.
• 2025-09-30: End of Q3 2025 Reporting Period — The period reflects a net loss of $46 million and a 5% increase in net sales, with significant impacts from divestitures and hurricane-related charges.

Glossary

Discontinued Operations

Assets and liabilities that have been disposed of or are classified as held for sale, and the results of operations of these assets. (The company's total assets decreased significantly due to the divestiture of discontinued operations, impacting the balance sheet structure.)

Accumulated other comprehensive loss

A component of equity that includes unrealized gains and losses that are not reported in net income. (This account shows a loss of $3.733 billion as of September 30, 2025, reflecting items like foreign currency translation adjustments.)

Noncontrolling interests

The portion of equity in a subsidiary that is not attributable to the parent company. (The company reported a negative noncontrolling interest of $27 million as of September 30, 2025, indicating a shift in ownership structure or subsidiary performance.)

Working capital adjustments

Changes made to the purchase price of an asset or business based on the difference between the actual working capital at closing and a target amount. (These adjustments reduced the pre-tax gain on the sale of the Kidney Care business by $55 million in Q3 2025.)

Year-Over-Year Comparison

Compared to the prior-year quarter, Baxter International Inc. experienced a significant shift from net income of $140 million to a net loss of $46 million, with basic EPS falling from $0.27 to a loss of $0.09. While net sales saw a 5% increase to $2.835 billion, gross margins declined, and cost of sales rose, indicating margin compression. Total assets have also decreased substantially due to the divestiture of discontinued operations, reflecting a strategic reshaping of the company's balance sheet.

Key Financial Figures

• $1.00 — ange on which registered Common Stock, $1.00 par value BAX (NYSE) New York Stock Exc

Filing Documents

• bax-20250930.htm (10-Q) — 2114KB
• bax-20250930xex101.htm (EX-10.1) — 84KB
• bax-20250930xex311.htm (EX-31.1) — 9KB
• bax-20250930xex312.htm (EX-31.2) — 9KB
• bax-20250930ex321.htm (EX-32.1) — 4KB
• bax-20250930xex322.htm (EX-32.2) — 4KB
• 0001628280-25-048897.txt ( ) — 12257KB
• bax-20250930.xsd (EX-101.SCH) — 75KB
• bax-20250930_cal.xml (EX-101.CAL) — 131KB
• bax-20250930_def.xml (EX-101.DEF) — 427KB
• bax-20250930_lab.xml (EX-101.LAB) — 905KB
• bax-20250930_pre.xml (EX-101.PRE) — 659KB
• bax-20250930_htm.xml (XML) — 2301KB

Financial Statements (unaudited)

Financial Statements (unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Income (Loss) 3 Condensed Consolidated Statements of Comprehensive Income (Loss) 4 Condensed Consolidated Statements of Changes in Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 55 Item 4.

Controls and Procedures

Controls and Procedures 56 PART II. OTHER INFORMATION 57 Item 1.

Legal Proceedings

Legal Proceedings 57

Risk Factors

Item 1A. Risk Factors 57 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 57

Other Information

Item 5. Other Information 57 Item 6. Exhibits 58 Signature 59

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Baxter International Inc. Condensed Consolidated Balance Sheets (unaudited) (in millions, except share information) September 30, 2025 December 31, 2024 Current assets: Cash and cash equivalents $ 1,726 1,764 Accounts receivable, net of allowances of $ 69 in 2025 and $ 71 2024 1,777 1,679 Inventories 2,460 2,046 Prepaid expenses and other current assets 970 753 Current assets of discontinued operations — 2,611 Total current assets 6,933 8,853 Property, plant and equipment, net 2,812 2,870 Goodwill 5,400 5,275 Other intangible assets, net 4,805 5,223 Operating lease right-of-use assets 270 306 Other non-current assets 847 755 Non-current assets of discontinued operations — 2,500 Total assets $ 21,067 $ 25,782 Current liabilities: Short-term debt $ 4 $ 2,126 Current maturities of long-term debt and finance lease obligations 751 626 Accounts payable 953 968 Accrued expenses and other current liabilities 2,067 1,861 Current liabilities of discontinued operations — 930 Total current liabilities 3,775 6,511 Long-term debt and finance lease obligations, less current portion 8,747 10,374 Operating lease liabilities 210 243 Other non-current liabilities 1,121 1,076 Non-current liabilities of discontinued operations — 554 Total liabilities 13,853 18,758 Commitments and contingencies Equity: Common stock, $ 1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2025 and 2024 683 683 Common stock in treasury, at cost, 169,548,900 shares in 2025 and 172,567,636 shares in 2024 ( 10,891 ) ( 11,059 ) Additional contributed capital 6,345 6,421 Retained earnings 14,837 14,929 Accumulated other comprehensive loss ( 3,733 ) ( 4,010 ) Total Baxter stockholders' equity 7,241 6,964 Noncontrolling interests ( 27 ) 60 Total equity 7,214 7,024 Total liabilities and equity $ 21,067 $ 25,782 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Baxter

View Full Filing

View this 10-Q filing on SEC EDGAR